- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Medical-Drugs
Orexigen Therapeutics Inc
+ Add to WatchlistOREX:US
6.0400 USD 0.0100 0.17%As of 20:10:00 ET on 05/17/2013.
Snapshot for Orexigen Therapeutics Inc (OREX)
| Open: | 6.1000 | Day's Range: | 6.0100 - 6.1200 | Volume: | 688,839 |
|---|---|---|---|---|---|
| Previous Close: | 6.0400 | 52wk Range: | 3.1000 - 7.7300 | 1-Yr Rtn: | +75.58% |
Key Statistics for OREX
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -1.3100 |
| Est. EPS (USD) (12/2013) | -0.7850 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 571.64 |
| Shares Outstanding (M) | 94.64 |
| 30 Day Average Volume | 840,197 |
| Price/Book (mrq) | 9.5468 |
| Price/Sale (ttm) | 133.6234 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/07/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for OREX
Company Profile & Key Executives for OREX
Orexigen Therapeutics Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of the central nervous system, or CNS, disorders with an initial focus on obesity.
| Michael Narachi "Mike"President/CEO | Mark D BoothChief Commercial Officer |
| Joseph P Hagan "Jay"Chief Bus Officer/Acting CFO | Heather D TurnerSenior VP/Secretary/Gen Cnsl |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
OREX News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page